Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Quintiles Launches New Testing Services in China | Contract Pharma

What are you searching for?

Sign in
Breaking News

Quintiles Launches New Testing Services in China

Quintiles expands central lab capabilities.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Quintiles has expanded its capabilities to include anatomic pathology services through its central lab in Beijing, China, in an effort to help biopharmaceutical companies develop more effective cancer treatments. These services complement assay development, digital pathology and core lab offerings available through the facility to help customers comply with China’s restrictions on tissue import/export.

“Within China, we are providing the tools and infrastructure to investigate cancer and match patients with optimum treatments for their genetic makeup,” said Christopher Ung, vice president strategic business and operations, Oncology for Quintiles. “These capabilities enable personalized medicine and enhance oncology research to bring medicines to market faster.”

Additionally, the Beijing anatomic pathology lab was accredited by the College of American Pathologists (CAP). This accreditation is issued following an on-site evaluation by a team of practicing lab professionals who examine records, quality control, staff qualifications, equipment, safety, and overall site management.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters